Sources, Coverage & Methodology
ChinaDrugStatus reconciles China mainland drug approval records (NMPA) with national basic medical insurance (NRDL) and commercial health insurance innovative drug catalogs (NHSA). Every structured field is manually verified and linked directly back to its official source document.
Primary Official Sources Registry
All records on this site are independently structured summaries linking to original agency URLs. Per the NMPA Website Statement ↗, verbatim commercial republication is avoided; users should inspect primary documents for legal or clinical authority.
| Authority | Document | Published | Retrieved |
|---|---|---|---|
| NHSA | Official Notice on 2026 National Reimbursement Drug List and Commercial Insurance Innovative Drug List ↗ 国家医保局 人力资源社会保障部关于印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》(2026年)的通知 Official government notice; structured facts summarized and linked to primary source. | 2026-11-14 | 2026-11-20 |
| NHSA | 2026 National Reimbursement Drug List (Official PDF) ↗ 国家基本医疗保险、生育保险和工伤保险药品目录(2026年) Official NHSA PDF attachment; page anchors point to exact PDF page numbers. | 2026-11-14 | 2026-11-20 |
| NHSA | 2026 Commercial Health Insurance Innovative Drug List (Official PDF) ↗ 商业健康保险创新药品目录(2026年) Official NHSA PDF attachment; listing is for commercial insurance reference and does not guarantee payout under all policies. | 2026-11-14 | 2026-11-20 |
| NHSA 医保发〔2025〕33号 | Official Notice on 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List ↗ 国家医保局 人力资源社会保障部关于印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新药品目录》(2025年)的通知 Baseline 2025 edition notice used for year-over-year diffing. | 2025-12-07 | 2026-11-20 |
| NHSA 医保发〔2025〕33号附件 | 2025 National Reimbursement Drug List (Official PDF) ↗ 国家基本医疗保险、生育保险和工伤保险药品目录(2025年) Official 2025 baseline NRDL PDF attachment used for 2025 vs 2026 verification. | 2025-12-07 | 2026-11-20 |
| NHSA 医保发〔2025〕33号附件 | 2025 Commercial Health Insurance Innovative Drug List (Official PDF) ↗ 商业健康保险创新药品目录(2025年) Official 2025 baseline Commercial List PDF attachment used for 2025 vs 2026 verification. | 2025-12-07 | 2026-11-20 |
| NMPA | NMPA Drug Approval Certificate Delivery Notice (2025-06-30 — Mazdutide Injection) ↗ 国家药监局药品批准证明文件送达信息(2025年06月30日) NMPA website statement restricts commercial verbatim reproduction; site publishes independent structured fields and links back to original page. | 2025-06-30 | 2026-11-20 |
| MAH | Innovent Biologics — Mazdutide Injection Prescribing Information (Official Label PDF) ↗ 玛仕度肽注射液说明书(信达生物) Official MAH prescribing information containing both 2025-06-24 weight management and 2025-09-16 T2D labels plus approval numbers H20250036–H20250038. | 2025-09-16 | 2026-11-20 |
| NMPA | NMPA Government Service & Drug Database Portal ↗ 国家药品监督管理局政务服务门户与药品查询 Primary official NMPA portal for verifying drug approval numbers and registration certificates. | — | 2026-11-20 |
| NMPA | NMPA Drug Regulatory Updates ↗ 国家药监局药品监管动态 Official NMPA announcements for innovative drug approvals and label expansions. | — | 2026-11-20 |
| WHO | WHO International Nonproprietary Names (INN) Guidance ↗ 世界卫生组织国际非专利药名(INN)指南 Authoritative reference for English generic (INN) naming alignment. | — | 2026-11-20 |
Status & Date Semantics
Active on or after the official catalog effective date (e.g., Jan 1, 2027 for 2026 editions).
Published in an official notice (Nov 14, 2026) but not yet effective as of the query date.
Removed from 2026 NRDL after non-renewal, with 6-month transition coverage under the original payment standard through Jun 30, 2027.
Field not yet manually confirmed from primary agency documentation; never guessed or fabricated.
Key Field Rules & Missing Data Markers
- Confidential Negotiated Prices (
*): Entries marked with an asterisk in NHSA PDFs remain unpublished per NHSA rules. Prices are left blank rather than estimated. - Approval Date vs Notice Date: NMPA certificate approval dates (核准日期) and delivery/announcement publication dates (发布日期) are stored in separate columns.
- Approved Scope vs Reimbursement Scope: NMPA-approved prescribing indications and NHSA-reimbursed payment limitations are tracked independently (e.g., Mazdutide is NMPA-approved for weight management and T2D, while 2026 NRDL covers adult T2D only).
- Update Cadence: NMPA approvals and corrections are checked weekly; NHSA catalog updates, errata, and transition notices are targeted for update within 2 business days while preserving historical editions.
Curated CSV Exports
Static site pages and downloadable CSV files are generated from the exact same audited records in data/, preserving source IDs, catalog editions, and verification dates.
Report a Correction or Request a Drug
Spotted a discrepancy in a catalog number, payment scope wording, approval number, or English INN mapping? Send the drug name, specific field, and official source link (NMPA, NHSA, or MAH label) and we will re-verify and update the dataset.